Desogestrel
Bekyree, Cyclessa, Desogestrel / Ethinyl Estradiol, Enskyce, Isibloom, Kalliga, Kariva, Pimtrea, Simliya, Velivet, Viorele, Volnea (desogestrel) is a small molecule pharmaceutical. Desogestrel was first approved as Desogen on 1992-12-10. It is used to treat acne vulgaris, endometriosis, and menstruation disturbances in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Combinations
Averi, Bekyree, Cyclessa, Desogestrel ethinyl estradiol, Enskyce, Isibloom, Kalliga, Kariva, Pimtrea, Simliya, Velivet, Viorele, Volnea (discontinued: Desogen, Desogestrel ethinyl estradiol, Emoquette, Kimidess, Mircette, Ortho-cept)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Desogestrel
+
Ethinyl estradiol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CYCLESSA | Aspen Global | N-021090 RX | 2000-12-20 | 1 products, RLD, RS |
Show 3 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| apri | ANDA | 2024-06-12 |
| averi | ANDA | 2025-06-05 |
| azurette | ANDA | 2025-09-08 |
| bekyree | ANDA | 2023-03-31 |
| caziant | ANDA | 2020-12-15 |
| cyred eq | ANDA | 2025-06-05 |
| desogestrel and ethinyl estradiol | ANDA | 2024-04-22 |
| desogestrel and ethinyl estradiol and ethinyl estradiol | ANDA | 2024-04-22 |
| enskyce | ANDA | 2025-07-08 |
| isibloom | ANDA | 2024-09-25 |
Show 10 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03A: Hormonal contraceptives for systemic use
— G03AA: Progestogens and estrogen systemic contraceptives, fixed combinations
— G03AA09: Desogestrel and ethinylestradiol
— G03AB: Progestogens and estrogens systemic contraceptives, sequential preparations
— G03AB05: Desogestrel and ethinylestradiol
— G03AC: Progestogen systemic hormonal contraceptives
— G03AC09: Desogestrel
— G03F: Progestogens and estrogens in combination
— G03FB: Progestogens and estrogens, sequential preparations
— G03FB10: Desogestrel and estrogen
HCPCS
No data
Clinical
Clinical Trials
94 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | — | — | — | — | 5 | 3 | 6 | 14 |
| Infertility | D007246 | EFO_0000545 | — | — | 1 | 3 | 5 | 3 | 11 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | 1 | 1 | 1 | — | 3 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | 2 | 1 | 3 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | 1 | 1 | 2 |
| Ovulation induction | D010062 | — | — | 1 | 1 | — | 1 | — | 2 |
| Bone diseases | D001847 | — | M89.9 | — | — | — | 2 | — | 2 |
| Drug interactions | D004347 | — | — | — | — | — | 1 | — | 1 |
| Tic disorders | D013981 | — | F95 | — | — | — | 1 | — | 1 |
| Developmental bone diseases | D001848 | — | — | — | — | — | 1 | — | 1 |
Show 11 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | — | B19.2 | — | — | 1 | — | 3 | 4 |
| Hepatitis | D006505 | — | K75.9 | — | — | 1 | — | 3 | 4 |
| Healthy volunteers/patients | — | — | — | 1 | 1 | 1 | — | — | 3 |
| Syndrome | D013577 | — | — | — | 3 | 1 | — | — | 3 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | 1 | — | 2 | 3 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | 1 | — | 2 | 3 |
| Endometriosis | D004715 | EFO_0001065 | N80 | — | 1 | 1 | — | 2 | 3 |
| Female infertility | D007247 | EFO_0008560 | N97 | — | — | 1 | — | 1 | 2 |
| Central sleep apnea | D020182 | — | G47.31 | — | 2 | 1 | — | — | 2 |
| Metrorrhagia | D008796 | — | N92.1 | — | — | 1 | — | 1 | 2 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemostasis | D006487 | — | — | — | 2 | — | — | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | — | — | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | 1 | — | — | — | 2 |
| Ovarian diseases | D010049 | — | — | — | 1 | — | — | — | 1 |
| Hypoventilation | D007040 | — | — | — | 1 | — | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 1 | — | — | — | — | 1 |
| Male genital neoplasms | D005834 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 7 | 7 |
| Bradycardia | D001919 | — | R00.1 | — | — | — | — | 4 | 4 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | — | 3 | 3 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | — | — | 2 | 2 |
| Fatty liver | D005234 | EFO_0003934 | — | — | — | — | — | 2 | 2 |
| Uterine hemorrhage | D014592 | — | — | — | — | — | — | 2 | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
| Atrioventricular block | D054537 | — | I44.3 | — | — | — | — | 2 | 2 |
| Bundle-branch block | D002037 | EFO_0004138 | I44.7 | — | — | — | — | 2 | 2 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 2 | 2 |
Show 37 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Desogestrel |
| INN | desogestrel |
| Description | Desogestrel is a 17beta-hydroxy steroid and a terminal acetylenic compound. It has a role as a contraceptive drug, a progestin and a synthetic oral contraceptive. |
| Classification | Small molecule |
| Drug class | estrogens; progestins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3C(=C)C[C@@]21CC |
Identifiers
| PDB | — |
| CAS-ID | 54024-22-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1533 |
| ChEBI ID | 4453 |
| PubChem CID | 40973 |
| DrugBank | DB00304 |
| UNII ID | 81K9V7M3A3 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Desogestrel
+
Ethinyl estradiol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,992 documents
View more details
Safety
Black-box Warning
Black-box warning for: Averi, Bekyree, Cyred eq, Desogestrel and ethinyl estradiol, Enskyce, Isibloom, Juleber, Kalliga, Kariva, Pimtrea, Simliya, Viorele
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,274 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use